SAN DIEGO, July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 7:55am PT | 10:55am ET.
A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida's website, . A replay of the webcast will be available for approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at and connect with Poseida on X and LinkedIn.
View original content to download multimedia:
SOURCE Poseida Therapeutics, Inc.
Poseida Investor and Media Relations: Alex Chapman, Senior Vice President, IR & Corporate Communications, IR@poseida.com; Sarah Thailing, Senior Director, IR & Corporate Communications, PR@poseida.com
Poseida Therapeutics,Inc.(纳斯达克:PSTX)是一家临床阶段异基因细胞疗法和基因医学公司,致力于推进非病毒治疗对于癌症和罕见疾病患者的差异化治疗。今天,该公司的总裁兼首席执行官Kristin Yarema博士将于2024年7月9日星期二上午7:55(PT)|上午10:55(ET)参加Stifel 2024虚拟细胞疗法论坛上的虚拟炉边聊天。
炉边聊天的现场网络直播将在Poseida网站的投资者和媒体部分提供。演示后约90天可提供网络直播的重播。
关于 Poseida Therapeutics, Inc.
Poseida Therapeutics是一家处于临床阶段的生物制药公司,推进具有治愈某些癌症和罕见疾病潜力的差异化异基因细胞疗法和基因医学。该公司的管道包括针对实体瘤和血液肿瘤的临床前CAR-T细胞疗法以及旨在满足高度医学需求的临床前体内基因药物。该公司的方法基于其专有的基因编辑平台,包括其非病毒piggyBac DNA递送系统、Cas-CLOVER位点特异性基因编辑系统、Booster分子和纳米颗粒基因递送技术以及内部GMP细胞疗法制造。该公司已与罗氏和爱卫方,形成战略合作,以开发针对癌症患者的细胞治疗的前景。欲了解更多信息,请访问 www.poseida.com,并在X和LinkedIn上关注Poseida。
查看下载多媒体原始内容:
来源 Poseida Therapeutics,Inc。
Poseida投资者和媒体关系:Alex Chapman,IR&Corporate Communications高级副总裁,IR@poseida.com; Sarah Thailing,IR&Corporate Communications高级总监,PR@poseida.com